Inovio Pharmaceuticals (INO) Times Interest Earned (2011 - 2026)
Inovio Pharmaceuticals (INO) posted Times Interest Earned of -$10.3 for Q1 2026, down 461.9% sequentially from -$1.83 in Q1 2025, and down 461.9% YoY from $2.84 in Q1 2025.
Inovio Pharmaceuticals (INO) Times Interest Earned (2011 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Times Interest Earned for 16 years, with the latest figure at -$10.3 in Q1 2026.
- Quarterly Times Interest Earned fell 461.9% year-over-year to -$10.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$39.27 (down 406.67% YoY) and the FY2025 annual result came in at -$0.23, up 28.73% from the prior year.
- Times Interest Earned declined to -$10.3 in Q1 2026 per INO's latest filing, from -$1.83 in the prior quarter.
- Over five years, Times Interest Earned peaked at $121973.4 in Q4 2024 and troughed at -$332.19 in Q2 2022.
- A 5-year average of $10069.1 and a median of -$92.52 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2026: Times Interest Earned jumped 118973.34% in 2024, then sank 461.9% in 2026.
- Over 5 years, Times Interest Earned stood at -$76.32 in 2022, then sank by 34.44% to -$102.61 in 2023, then surged by 118973.34% to $121973.4 in 2024, then sank by 100.0% to -$1.83 in 2025, then tumbled by 461.9% to -$10.3 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$10.3, -$1.83, and $121973.4 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.01 |
| Mar 31, 2026 | -10.30 |
| Mar 31, 2025 | -1.83 |
| Dec 31, 2024 | 121,973.42 |
| Mar 31, 2024 | -59.02 |
| Dec 31, 2023 | -102.61 |
| Sep 30, 2023 | -113.41 |
| Jun 30, 2023 | -118.16 |
| Mar 31, 2023 | -82.43 |
| Dec 31, 2022 | -76.32 |
| Sep 30, 2022 | -114.06 |
| Jun 30, 2022 | -332.19 |
| Mar 31, 2022 | -134.46 |
| Dec 31, 2021 | 278.88 |
| Sep 30, 2021 | -125.85 |
| Jun 30, 2021 | -178.27 |
| Mar 31, 2021 | -96.55 |
| Dec 31, 2020 | -27.47 |
| Sep 30, 2020 | -18.31 |
| Jun 30, 2020 | -11.66 |